Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes

• DOI: 10.1016/j.kint.2022.04.022
• Publication Date: 2022-05-24T00:38:24Z
• Authors: Hiroki Kobayashi; Helen C. Looker; Eiichiro Satake; Pierre Jean Saulnier; Zaipul I. Md Dom; Kristina O’Neil; Katsuhito Ihara; Bozena Krolewski; Andrzej T. Galecki; Monika A. Niewczas; Jonathan M. Wilson; Alessandro Doria; Kevin L. Duffin; Robert G. Nelson; Andrzej S. Krolewski
• Keywords: Proteomics; Diabetes Mellitus, Type 2; Disease Progression; Humans; Diabetic Nephropathies; Lectins, C-Type; Renal Insufficiency; Biomarkers; Endostatins; 3. Good health

This study applies a large proteomics panel to search for new circulating biomarkers associated with progression kidney failure in individuals diabetic disease. Four independent cohorts encompassing 754 type 1 and 2 diabetes early late disease were followed ascertain failure. During ten years of follow-up, 227 progressed Using the SOMAscan platform, we measured baseline concentration 1129 proteins. In our previous publications, analyzed 334 these proteins that members specific candidate pathways involved found 35 strongly risk Here, examined remaining 795 using an untargeted approach. Of proteins, 11 significantly Biological processes previously reported related neuron development (DLL1, MATN2, NRX1B, KLK8, RTN4R ROR1) implicated fibrosis (LAYN, DLL1, MAPK11, endostatin, cellular animal studies. Specific mechanisms underlie involvement must be further investigated assess their value as targets kidney-protective therapies. multivariable LASSO regression analysis, five ESAM, MAPK11 endostatin) independently Thus, identified may considered prognostic predict Furthermore, three MAPK11) selected when all results evaluated.